Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122549 · ClinicalTrials.gov registry record · NA
Hospital Wearable Defibrillator Inpatient Study
A NA study of In-hospital Cardiac Arrest, sponsored by Zoll Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
- 8
- Study locations
NCT02122549: Completed NA study of In-hospital Cardiac Arrest, sponsored by Zoll Medical Corporation.
NCT02122549 is a NA study of In-hospital Cardiac Arrest that has completed, run by Zoll Medical Corporation. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02122549, a NA study of In-hospital Cardiac Arrest, has completed, sponsored by Zoll Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will obtain device-human interaction evaluations for the HWD1000 within the controlled environment of the hospital as well as establish that the safety profile is similar to outpatient wearable cardioverter-defibrillators use.
Primary Outcome
The amount of time that the HWD1000 is unable to monitor the subject's rhythm status is the primary safety measure. The specific goals are that average monitoring will be inhibited by noise no greater than 2% of the time worn (at least 24 hours) and monitoring using single lead analysis will be no greater than 5% of the time worn (at least 24 hours).
Conditions Studied
Interventions
- DEVICE HWD1000
Study Locations (8)
Florida
- - Atlantis
- - Jupiter
California
- - Los Angeles
Connecticut
- - Danbury
Iowa
- - Iowa City
Minnesota
- - Saint Paul
Virginia
- - Richmond
Washington
- - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-07 |
| Phase | NA |
What the finished NCT02122549 record still lists
NCT02122549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with In-hospital Cardiac Arrest appearing as the primary indexed condition, and to 1 intervention - of which HWD1000 is the first listed.
NCT02122549 lists 8 locations in 7 states (Florida, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02122549 about?
NCT02122549 is a clinical study titled "Hospital Wearable Defibrillator Inpatient Study". This study will obtain device-human interaction evaluations for the HWD1000 within the controlled environment of the hospital as well as establish that the safety profile is similar to outpatient wearable cardioverter-defibrillators use.
What is the current status of trial NCT02122549?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2014-04. Estimated completion is 2015-07.
What conditions does trial NCT02122549 study?
This clinical trial studies the following conditions: In-hospital Cardiac Arrest.
What interventions are being tested in trial NCT02122549?
The interventions under investigation include: HWD1000 (DEVICE).
Who is sponsoring clinical trial NCT02122549?
This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02122549 being conducted?
This trial has 8 study locations across California, Connecticut, Florida, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for In-hospital Cardiac Arrest
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02122549's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia